<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="brief-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">1755</journal-id><journal-id journal-id-type="pmc-domain">frontonco</journal-id><journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id><journal-title-group><journal-title>Frontiers in Oncology</journal-title></journal-title-group><issn pub-type="epub">2234-943X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11840873</article-id><article-id pub-id-type="pmcid-ver">PMC11840873.1</article-id><article-id pub-id-type="pmcaid">11840873</article-id><article-id pub-id-type="pmcaiid">11840873</article-id><article-id pub-id-type="pmid">39980547</article-id><article-id pub-id-type="doi">10.3389/fonc.2025.1470387</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Oncology</subject><subj-group><subject>Brief Research Report</subject></subj-group></subj-group></article-categories><title-group><article-title>Characteristics, treatment patterns, and biomarker testing of patients with advanced <italic toggle="yes">RET</italic> fusion-positive non-small cell lung cancer in a real-world multi-country observational study: a brief report</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Kiiskinen</surname><given-names initials="U">Urpo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2801148"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Segall</surname><given-names initials="G">Grace</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2958091"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bailey</surname><given-names initials="H">Hollie</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Forshaw</surname><given-names initials="C">Cameron</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2920134"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Puri</surname><given-names initials="T">Tarun</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1863384"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Eli Lilly and Company</institution>, <addr-line>Indianapolis, IN</addr-line>, <country>United States</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Adelphi Real World</institution>, <addr-line>Bollington, Cheshire</addr-line>, <country>United Kingdom</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Lin Zhou, Capital Medical University, China</p></fn><fn fn-type="edited-by"><p>Reviewed by: Eswari Dodagatta-Marri, University of California, San Francisco, United States</p><p>Elena Lastraioli, University of Florence, Italy</p></fn><corresp id="fn001">*Correspondence: Urpo Kiiskinen, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:kiiskinen_urpo@lilly.com">kiiskinen_urpo@lilly.com</email></corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">480898</issue-id><elocation-id>1470387</elocation-id><history><date date-type="received"><day>25</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>20</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-24 01:25:30.443"><day>24</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Kiiskinen, Segall, Bailey, Forshaw and Puri</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Kiiskinen, Segall, Bailey, Forshaw and Puri</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fonc-15-1470387.pdf"/><abstract><sec><title>Introduction</title><p>Approximately 1&#8722;2% of non-small cell lung cancers (NSCLCs) are positive for rearranged during transfection (<italic toggle="yes">RET</italic>) gene fusions. The aim of this real-world multi-national study was to describe clinical characteristics, biomarker testing, and treatment patterns of patients with <italic toggle="yes">RET</italic> fusion-positive NSCLC.</p></sec><sec><title>Methods</title><p>This observational study was conducted in 2020 in nine countries using electronic patient record forms, following Adelphi Disease Specific Programme (DSP&#8482;) methodology. Patients with advanced NSCLC (aNSCLC) were included in the overall cohort. A smaller <italic toggle="yes">RET</italic> fusion-positive cohort comprised patients from the overall aNSCLC cohort who had <italic toggle="yes">RET</italic> fusion-positive disease and no other co-alterations, plus an oversample of patients with <italic toggle="yes">RET</italic> fusion-positive disease and no other co-alterations.</p></sec><sec><title>Results</title><p>Patient characteristics were generally similar between the overall aNSCLC cohort (n=2947) and the <italic toggle="yes">RET</italic> fusion-positive cohort (n=576), aside from higher proportions of White/Caucasian patients, never smokers, and adenocarcinoma among the <italic toggle="yes">RET</italic> fusion-positive cohort. For the overall aNSCLC cohort, 899 (31%) were tested for <italic toggle="yes">RET</italic> fusions; 84% of <italic toggle="yes">RET</italic> test results were available prior to initiation of aNSCLC treatment. Comparisons between the two cohorts showed similar proportions of patients treated with chemotherapy (&#177; immunotherapy), but less use of immunotherapy only or targeted therapy in the <italic toggle="yes">RET</italic> fusion-positive cohort.</p></sec><sec><title>Conclusions</title><p>Results of this real-world study provide insights into clinical characteristics, biomarker testing, and treatment patterns of patients with <italic toggle="yes">RET</italic> fusion-positive aNSCLC and highlight the need for awareness and education to increase <italic toggle="yes">RET</italic> testing with the intent to treat with selective RET inhibitors when appropriate to optimize outcomes for patients.</p></sec></abstract><kwd-group><kwd>clinical characteristics</kwd><kwd>treatment patterns</kwd><kwd>biomarker testing</kwd><kwd><italic toggle="yes">RET</italic> fusion-positive non-small cell lung cancer</kwd><kwd>real-world data</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Eli Lilly and Company
</institution><institution-id institution-id-type="doi">10.13039/100004312</institution-id></institution-wrap></funding-source></award-group><funding-statement>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The study was funded by Eli Lilly and Company.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="3"/><equation-count count="0"/><ref-count count="14"/><page-count count="8"/><word-count count="2998"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Thoracic Oncology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Non-small cell lung cancer (NSCLC) represents approximately 80&#8722;90% of all lung cancers (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Recently, treatment options for patients with advanced NSCLC (aNSCLC) have greatly expanded with the identification of targetable oncogenic driver alterations and the regulatory approval of several targeted therapies. One of these biomarkers is rearranged during transfection (<italic toggle="yes">RET</italic>) (<xref rid="B3" ref-type="bibr">3</xref>). Approximately 1&#8722;2% of all NSCLCs are positive for <italic toggle="yes">RET</italic> gene fusions (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). Targeted treatments for <italic toggle="yes">RET</italic> fusion-positive aNSCLC include the selective RET kinase inhibitors selpercatinib and pralsetinib (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>).</p><p>Understanding real-world patient characteristics and treatment patterns, alongside more comprehensive information on biomarker testing, can provide important context for the rapidly evolving landscape of aNSCLC therapy and aid the generalizability of clinical trial data to routine clinical practice. The aim of this real-world multi-national study was to describe the clinical characteristics, biomarker testing, and treatment patterns of patients with <italic toggle="yes">RET</italic> fusion-positive aNSCLC.</p></sec><sec sec-type="materials|methods" id="s2"><label>2</label><title>Material and methods</title><p>This observational study was conducted from July to December 2020 in nine countries (Brazil, France, Germany, Italy, Japan, Spain, Taiwan, the UK, and the USA) following Adelphi DSP&#8482; methodology, which involves large, multinational, cross-sectional surveys that collect real-world data from physicians and patients (<xref rid="B8" ref-type="bibr">8</xref>). Here, we report on patient-level data using electronic patient record forms (ePRFs) completed by physicians.</p><sec id="s2_1"><label>2.1</label><title>Recruitment, eligibility criteria, and data collection</title><p>Oncologists and pulmonologists (and respiratory surgeons in Japan) were identified using publicly available lists of clinicians in each country. Eligible specialists were responsible for managing patients with aNSCLC and saw at least three patients with a diagnosis of aNSCLC per month. A sample was then randomly selected from willing clinicians meeting the inclusion criteria.</p><p>Clinicians completed an online anonymized ePRF based on prior medical records for six consulting eligible patients with aNSCLC who were included in a pseudorandom sample (hereafter referred to as the overall aNSCLC cohort). An additional two patients were part of an oversample of patients with <italic toggle="yes">RET</italic> fusion-positive aNSCLC and no other co-alterations (hereafter referred to as the <italic toggle="yes">RET</italic> fusion-positive cohort). This latter cohort also included patients from the overall aNSCLC cohort whose disease was <italic toggle="yes">RET</italic> fusion-positive with no other co-alterations (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>). Japanese patients were excluded from the <italic toggle="yes">RET</italic> fusion-positive cohort because <italic toggle="yes">RET</italic> fusion testing was not actively conducted in Japan at the time. Eligible patients were &#8805;18 years old, not participating in a clinical trial, and had a diagnosis of aNSCLC.</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Schematic flow chart showing study design. aNSCLC, advanced non-small cell lung cancer; <italic toggle="yes">RET</italic>, rearranged during transfection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fonc-15-1470387-g001.jpg"/></fig></sec><sec id="s2_2"><label>2.2</label><title>Study variables</title><p>Physicians provided information on patient demographics, clinical characteristics, biomarker testing, and first-line treatment. In particular, the ePRFs captured individual patient data on <italic toggle="yes">RET</italic> testing, including whether <italic toggle="yes">RET</italic> testing was conducted, results of <italic toggle="yes">RET</italic> testing, and whether next-generation sequencing (NGS) was used.</p></sec><sec id="s2_3"><label>2.3</label><title>Statistical analyses</title><p>Descriptive statistics are provided for demographics and disease characteristics, using median with interquartile range (IQR) for continuous variables, and the frequency and percentage within each category for categorical variables. Missing data were excluded from the analysis and no imputation was conducted.</p></sec><sec id="s2_4"><label>2.4</label><title>Ethical considerations</title><p>Data collection was in line with European Pharmaceutical Marketing Research Association guidelines (<xref rid="B9" ref-type="bibr">9</xref>). Study materials and protocol were reviewed and exempted by the Western Institutional Review Board (study protocol number AG8757) and were in full accordance with relevant legislation at the time of data collection (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>).</p></sec></sec><sec sec-type="results" id="s3"><label>3</label><title>Results</title><p>Demographic and clinical characteristic data were available for 2947 patients in the overall aNSCLC cohort and 576 patients in the <italic toggle="yes">RET</italic> fusion-positive cohort (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>). Characteristics were generally similar between these cohorts for most parameters, including median age (67 [IQR 60&#8722;72] years vs. 65 [IQR 57&#8722;70] years), presence of central nervous system metastases, and programmed cell death ligand 1 (PD-L1) expression, and with most patients in each cohort being male, having stage IV disease and Eastern Cooperative Oncology Group performance status (ECOG PS) 0&#8722;1 (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>). Median age for the overall aNSCLC cohort was similar across the nine countries (data not shown).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Patient demographic and clinical characteristics in the overall aNSCLC population and in patients with <italic toggle="yes">RET</italic> fusion-positive aNSCLC and no other co-alterations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1">Characteristic</th><th valign="top" colspan="2" align="center" rowspan="1">Overall aNSCLC (n=2947)<xref rid="fnT1_1" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th valign="top" colspan="2" align="center" rowspan="1">
<italic toggle="yes">RET</italic> fusion-positive aNSCLC<xref rid="fnT1_2" ref-type="table-fn">
<sup>b</sup>
</xref> (n=576)<xref rid="fnT1_1" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age, median (IQR), years</td><td valign="top" align="center" rowspan="1" colspan="1">67</td><td valign="top" align="center" rowspan="1" colspan="1">(60&#8722;72)</td><td valign="top" align="center" rowspan="1" colspan="1">65</td><td valign="top" align="center" rowspan="1" colspan="1">(57&#8722;70)</td></tr><tr><th valign="top" colspan="5" align="left" rowspan="1">Sex, n (%)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Male</td><td valign="top" align="center" rowspan="1" colspan="1">1788</td><td valign="top" align="center" rowspan="1" colspan="1">(61)</td><td valign="top" align="center" rowspan="1" colspan="1">327</td><td valign="top" align="center" rowspan="1" colspan="1">(57)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Female</td><td valign="top" align="center" rowspan="1" colspan="1">1159</td><td valign="top" align="center" rowspan="1" colspan="1">(39)</td><td valign="top" align="center" rowspan="1" colspan="1">249</td><td valign="top" align="center" rowspan="1" colspan="1">(43)</td></tr><tr><th valign="top" colspan="5" align="left" rowspan="1">Ethnic origin, n (%)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;White/Caucasian</td><td valign="top" align="center" rowspan="1" colspan="1">2017</td><td valign="top" align="center" rowspan="1" colspan="1">(68)</td><td valign="top" align="center" rowspan="1" colspan="1">486</td><td valign="top" align="center" rowspan="1" colspan="1">(84)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Japanese</td><td valign="top" align="center" rowspan="1" colspan="1">324</td><td valign="top" align="center" rowspan="1" colspan="1">(11)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">(0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Han Chinese</td><td valign="top" align="center" rowspan="1" colspan="1">293</td><td valign="top" align="center" rowspan="1" colspan="1">(10)</td><td valign="top" align="center" rowspan="1" colspan="1">27</td><td valign="top" align="center" rowspan="1" colspan="1">(5)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;African American</td><td valign="top" align="center" rowspan="1" colspan="1">76</td><td valign="top" align="center" rowspan="1" colspan="1">(3)</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="center" rowspan="1" colspan="1">(2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Hispanic/Latino</td><td valign="top" align="center" rowspan="1" colspan="1">50</td><td valign="top" align="center" rowspan="1" colspan="1">(2)</td><td valign="top" align="center" rowspan="1" colspan="1">13</td><td valign="top" align="center" rowspan="1" colspan="1">(2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Other</td><td valign="top" align="center" rowspan="1" colspan="1">187</td><td valign="top" align="center" rowspan="1" colspan="1">(6)</td><td valign="top" align="center" rowspan="1" colspan="1">38</td><td valign="top" align="center" rowspan="1" colspan="1">(7)</td></tr><tr><th valign="top" colspan="5" align="left" rowspan="1">Smoking status, n (%)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Current smoker</td><td valign="top" align="center" rowspan="1" colspan="1">455</td><td valign="top" align="center" rowspan="1" colspan="1">(15)</td><td valign="top" align="center" rowspan="1" colspan="1">46</td><td valign="top" align="center" rowspan="1" colspan="1">(8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Former smoker</td><td valign="top" align="center" rowspan="1" colspan="1">1779</td><td valign="top" align="center" rowspan="1" colspan="1">(60)</td><td valign="top" align="center" rowspan="1" colspan="1">306</td><td valign="top" align="center" rowspan="1" colspan="1">(53)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Never smoked</td><td valign="top" align="center" rowspan="1" colspan="1">669</td><td valign="top" align="center" rowspan="1" colspan="1">(23)</td><td valign="top" align="center" rowspan="1" colspan="1">208</td><td valign="top" align="center" rowspan="1" colspan="1">(36)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Unknown</td><td valign="top" align="center" rowspan="1" colspan="1">44</td><td valign="top" align="center" rowspan="1" colspan="1">(1)</td><td valign="top" align="center" rowspan="1" colspan="1">16</td><td valign="top" align="center" rowspan="1" colspan="1">(3)</td></tr><tr><th valign="top" colspan="5" align="left" rowspan="1">Disease stage at initial diagnosis, n (%)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Stage I</td><td valign="top" align="center" rowspan="1" colspan="1">50</td><td valign="top" align="center" rowspan="1" colspan="1">(2)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">(&lt;1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Stage II</td><td valign="top" align="center" rowspan="1" colspan="1">101</td><td valign="top" align="center" rowspan="1" colspan="1">(3)</td><td valign="top" align="center" rowspan="1" colspan="1">16</td><td valign="top" align="center" rowspan="1" colspan="1">(3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Stage III</td><td valign="top" align="center" rowspan="1" colspan="1">634</td><td valign="top" align="center" rowspan="1" colspan="1">(22)</td><td valign="top" align="center" rowspan="1" colspan="1">81</td><td valign="top" align="center" rowspan="1" colspan="1">(14)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;&#8195;IIIA</td><td valign="top" align="center" rowspan="1" colspan="1">96</td><td valign="top" align="center" rowspan="1" colspan="1">(3)</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">(1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;&#8195;IIIB</td><td valign="top" align="center" rowspan="1" colspan="1">337</td><td valign="top" align="center" rowspan="1" colspan="1">(11)</td><td valign="top" align="center" rowspan="1" colspan="1">33</td><td valign="top" align="center" rowspan="1" colspan="1">(6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;&#8195;IIIC</td><td valign="top" align="center" rowspan="1" colspan="1">201</td><td valign="top" align="center" rowspan="1" colspan="1">(7)</td><td valign="top" align="center" rowspan="1" colspan="1">42</td><td valign="top" align="center" rowspan="1" colspan="1">(7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Stage IV</td><td valign="top" align="center" rowspan="1" colspan="1">2138</td><td valign="top" align="center" rowspan="1" colspan="1">(73)</td><td valign="top" align="center" rowspan="1" colspan="1">471</td><td valign="top" align="center" rowspan="1" colspan="1">(82)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Unknown/not assessed</td><td valign="top" align="center" rowspan="1" colspan="1">24</td><td valign="top" align="center" rowspan="1" colspan="1">(1)</td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td valign="top" align="center" rowspan="1" colspan="1">(1)</td></tr><tr><th valign="top" colspan="5" align="left" rowspan="1">Histology, n (%)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Adenocarcinoma</td><td valign="top" align="center" rowspan="1" colspan="1">2064</td><td valign="top" align="center" rowspan="1" colspan="1">(70)</td><td valign="top" align="center" rowspan="1" colspan="1">509</td><td valign="top" align="center" rowspan="1" colspan="1">(88)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Squamous cell carcinoma</td><td valign="top" align="center" rowspan="1" colspan="1">746</td><td valign="top" align="center" rowspan="1" colspan="1">(25)</td><td valign="top" align="center" rowspan="1" colspan="1">36</td><td valign="top" align="center" rowspan="1" colspan="1">(6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Large cell carcinoma</td><td valign="top" align="center" rowspan="1" colspan="1">93</td><td valign="top" align="center" rowspan="1" colspan="1">(3)</td><td valign="top" align="center" rowspan="1" colspan="1">24</td><td valign="top" align="center" rowspan="1" colspan="1">(4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Other</td><td valign="top" align="center" rowspan="1" colspan="1">33</td><td valign="top" align="center" rowspan="1" colspan="1">(1)</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">(1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Unknown/not assessed</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="center" rowspan="1" colspan="1">(&lt;1)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">(&lt;1)</td></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">ECOG PS score at advanced diagnosis, n (%)</th><th valign="top" colspan="2" align="center" rowspan="1">(base n=2941)</th><th valign="top" colspan="2" align="center" rowspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;0&#8722;1</td><td valign="top" align="center" rowspan="1" colspan="1">2292</td><td valign="top" align="center" rowspan="1" colspan="1">(78)</td><td valign="top" align="center" rowspan="1" colspan="1">458</td><td valign="top" align="center" rowspan="1" colspan="1">(80)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;2</td><td valign="top" align="center" rowspan="1" colspan="1">431</td><td valign="top" align="center" rowspan="1" colspan="1">(15)</td><td valign="top" align="center" rowspan="1" colspan="1">69</td><td valign="top" align="center" rowspan="1" colspan="1">(12)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;&#8805;3</td><td valign="top" align="center" rowspan="1" colspan="1">183</td><td valign="top" align="center" rowspan="1" colspan="1">(6)</td><td valign="top" align="center" rowspan="1" colspan="1">44</td><td valign="top" align="center" rowspan="1" colspan="1">(8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Unknown/not assessed</td><td valign="top" align="center" rowspan="1" colspan="1">35</td><td valign="top" align="center" rowspan="1" colspan="1">(1)</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">(1)</td></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Presence of CNS metastases at any time (primary site), n (%)</th><th valign="top" colspan="2" align="center" rowspan="1">(base n=2439)</th><th valign="top" colspan="2" align="center" rowspan="1">(base n=518)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Brain</td><td valign="top" align="center" rowspan="1" colspan="1">189</td><td valign="top" align="center" rowspan="1" colspan="1">(8)</td><td valign="top" align="center" rowspan="1" colspan="1">30</td><td valign="top" align="center" rowspan="1" colspan="1">(6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Other CNS</td><td valign="top" align="center" rowspan="1" colspan="1">54</td><td valign="top" align="center" rowspan="1" colspan="1">(2)</td><td valign="top" align="center" rowspan="1" colspan="1">24</td><td valign="top" align="center" rowspan="1" colspan="1">(5)</td></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Presence of CNS metastases at any time (secondary site), n (%)</th><th valign="top" colspan="2" align="center" rowspan="1">(base n=2439)</th><th valign="top" colspan="2" align="center" rowspan="1">(base n=518)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Brain</td><td valign="top" align="center" rowspan="1" colspan="1">228</td><td valign="top" align="center" rowspan="1" colspan="1">(9)</td><td valign="top" align="center" rowspan="1" colspan="1">32</td><td valign="top" align="center" rowspan="1" colspan="1">(6)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Other CNS</td><td valign="top" align="center" rowspan="1" colspan="1">72</td><td valign="top" align="center" rowspan="1" colspan="1">(3)</td><td valign="top" align="center" rowspan="1" colspan="1">19</td><td valign="top" align="center" rowspan="1" colspan="1">(4)</td></tr><tr><th valign="top" colspan="5" align="left" rowspan="1">PD-L1 expression, n (%)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;&lt;1%</td><td valign="top" align="center" rowspan="1" colspan="1">560</td><td valign="top" align="center" rowspan="1" colspan="1">(19)</td><td valign="top" align="center" rowspan="1" colspan="1">179</td><td valign="top" align="center" rowspan="1" colspan="1">(31)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;1&#8722;49%</td><td valign="top" align="center" rowspan="1" colspan="1">1182</td><td valign="top" align="center" rowspan="1" colspan="1">(40)</td><td valign="top" align="center" rowspan="1" colspan="1">248</td><td valign="top" align="center" rowspan="1" colspan="1">(43)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;&#8805;50%</td><td valign="top" align="center" rowspan="1" colspan="1">692</td><td valign="top" align="center" rowspan="1" colspan="1">(23)</td><td valign="top" align="center" rowspan="1" colspan="1">66</td><td valign="top" align="center" rowspan="1" colspan="1">(11)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;Unknown/not assessed</td><td valign="top" align="center" rowspan="1" colspan="1">513</td><td valign="top" align="center" rowspan="1" colspan="1">(17)</td><td valign="top" align="center" rowspan="1" colspan="1">83</td><td valign="top" align="center" rowspan="1" colspan="1">(14)</td></tr></tbody></table><table-wrap-foot><fn id="fnT1_1"><label>a</label><p>Number of patients with data for each parameter unless indicated otherwise.</p></fn><fn id="fnT1_2"><label>b</label><p>Without other co-alterations.</p></fn><fn><p>aNSCLC, advanced non-small cell lung cancer; CNS, central nervous system; ECOG PS, European Cooperative Oncology Group performance status; IQR, interquartile range; PD-L1, programmed cell death ligand 1; <italic toggle="yes">RET</italic>, rearranged during transfection.</p></fn></table-wrap-foot></table-wrap><p>Although statistical comparisons were not made, there were notable numerical differences between the overall aNSCLC cohort and the <italic toggle="yes">RET</italic> fusion-positive cohort for some parameters, including higher proportions of White/Caucasian patients (68% vs. 84%), never smokers (23% vs. 36%), and histology of adenocarcinoma (70% vs. 88%), and lower proportion of squamous cell carcinoma (25% vs. 6%), in the <italic toggle="yes">RET</italic> fusion-positive cohort. All comparisons between cohorts came with a caveat that the <italic toggle="yes">RET</italic> fusion-positive cohort excluded Japanese patients and included a small number of patients from the overall cohort. In the <italic toggle="yes">RET</italic> fusion-positive cohort, there was wide variation in the proportion of never smokers across countries, ranging from 24% and 31% in France and the USA, respectively, to 70% in Taiwan (data not shown).</p><p>The testing rate for <italic toggle="yes">RET</italic> gene fusions at diagnosis of advanced disease was 31% (899 of 2947 patients) in the overall aNSCLC cohort, but varied widely across countries, from 8% in Taiwan to 67% in the USA (<xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>). Testing for epidermal growth factor receptor (<italic toggle="yes">EGFR</italic>) mutations was more consistent across countries, ranging from 73% in Brazil to 90% in Taiwan. In general, the USA had the highest rates of testing across all biomarkers (<xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>). For patients in the overall aNSCLC cohort with available results (n=820), the prevalence of <italic toggle="yes">RET</italic> gene fusions was 4.8%, but was as high as 26.8% in Brazil. Most patients (77%) had been tested using NGS, and 84% had test results available prior to initiation of treatment for advanced disease (<xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table&#160;2</label><caption><p>Biomarker testing for the overall aNSCLC cohort and breakdown by country.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1">Parameter</th><th valign="top" align="center" rowspan="1" colspan="1">Overall aNSCLC<break/>(n=2947)<xref rid="fnT2_1" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th valign="top" align="center" rowspan="1" colspan="1">USA<break/>(n=470)<xref rid="fnT2_1" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th valign="top" align="center" rowspan="1" colspan="1">Brazil (n=289)<xref rid="fnT2_1" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th valign="top" align="center" rowspan="1" colspan="1">UK<break/>(n=295)<xref rid="fnT2_1" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th valign="top" align="center" rowspan="1" colspan="1">Italy<break/>(n=301)<xref rid="fnT2_1" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th valign="top" align="center" rowspan="1" colspan="1">France (n=366)<xref rid="fnT2_1" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th valign="top" align="center" rowspan="1" colspan="1">Spain (n=300)<xref rid="fnT2_1" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th valign="top" align="center" rowspan="1" colspan="1">Germany (n=302)<xref rid="fnT2_1" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th valign="top" align="center" rowspan="1" colspan="1">Taiwan (n=300)<xref rid="fnT2_1" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th valign="top" align="center" rowspan="1" colspan="1">Japan (n=324)<xref rid="fnT2_1" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr></thead><tbody><tr><th valign="top" colspan="11" align="left" rowspan="1">Biomarkers tested, n (%)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;RET</td><td valign="top" align="center" rowspan="1" colspan="1">899 (31)</td><td valign="top" align="center" rowspan="1" colspan="1">313 (67)</td><td valign="top" align="center" rowspan="1" colspan="1">85 (29)</td><td valign="top" align="center" rowspan="1" colspan="1">52 (18)</td><td valign="top" align="center" rowspan="1" colspan="1">82 (27)</td><td valign="top" align="center" rowspan="1" colspan="1">147 (40)</td><td valign="top" align="center" rowspan="1" colspan="1">86 (29)</td><td valign="top" align="center" rowspan="1" colspan="1">62 (21)</td><td valign="top" align="center" rowspan="1" colspan="1">25 (8)</td><td valign="top" align="center" rowspan="1" colspan="1">47 (15)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;PD-L1</td><td valign="top" align="center" rowspan="1" colspan="1">2487 (84)</td><td valign="top" align="center" rowspan="1" colspan="1">392 (83)</td><td valign="top" align="center" rowspan="1" colspan="1">216 (75)</td><td valign="top" align="center" rowspan="1" colspan="1">277 (94)</td><td valign="top" align="center" rowspan="1" colspan="1">278 (92)</td><td valign="top" align="center" rowspan="1" colspan="1">349 (95)</td><td valign="top" align="center" rowspan="1" colspan="1">288 (96)</td><td valign="top" align="center" rowspan="1" colspan="1">218 (72)</td><td valign="top" align="center" rowspan="1" colspan="1">220 (73)</td><td valign="top" align="center" rowspan="1" colspan="1">249 (77)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;EGFR</td><td valign="top" align="center" rowspan="1" colspan="1">2461 (84)</td><td valign="top" align="center" rowspan="1" colspan="1">419 (89)</td><td valign="top" align="center" rowspan="1" colspan="1">210 (73)</td><td valign="top" align="center" rowspan="1" colspan="1">235 (80)</td><td valign="top" align="center" rowspan="1" colspan="1">266 (88)</td><td valign="top" align="center" rowspan="1" colspan="1">297 (81)</td><td valign="top" align="center" rowspan="1" colspan="1">251 (84)</td><td valign="top" align="center" rowspan="1" colspan="1">246 (81)</td><td valign="top" align="center" rowspan="1" colspan="1">270 (90)</td><td valign="top" align="center" rowspan="1" colspan="1">267 (82)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;ALK</td><td valign="top" align="center" rowspan="1" colspan="1">2294 (78)</td><td valign="top" align="center" rowspan="1" colspan="1">391 (83)</td><td valign="top" align="center" rowspan="1" colspan="1">190 (66)</td><td valign="top" align="center" rowspan="1" colspan="1">235 (80)</td><td valign="top" align="center" rowspan="1" colspan="1">264 (88)</td><td valign="top" align="center" rowspan="1" colspan="1">289 (79)</td><td valign="top" align="center" rowspan="1" colspan="1">245 (82)</td><td valign="top" align="center" rowspan="1" colspan="1">210 (70)</td><td valign="top" align="center" rowspan="1" colspan="1">236 (79)</td><td valign="top" align="center" rowspan="1" colspan="1">234 (72)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;ROS1</td><td valign="top" align="center" rowspan="1" colspan="1">1881 (64)</td><td valign="top" align="center" rowspan="1" colspan="1">364 (77)</td><td valign="top" align="center" rowspan="1" colspan="1">131 (45)</td><td valign="top" align="center" rowspan="1" colspan="1">189 (64)</td><td valign="top" align="center" rowspan="1" colspan="1">223 (74)</td><td valign="top" align="center" rowspan="1" colspan="1">244 (67)</td><td valign="top" align="center" rowspan="1" colspan="1">229 (76)</td><td valign="top" align="center" rowspan="1" colspan="1">137 (45)</td><td valign="top" align="center" rowspan="1" colspan="1">188 (63)</td><td valign="top" align="center" rowspan="1" colspan="1">176 (54)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;KRAS</td><td valign="top" align="center" rowspan="1" colspan="1">1200 (41)</td><td valign="top" align="center" rowspan="1" colspan="1">336 (71)</td><td valign="top" align="center" rowspan="1" colspan="1">100 (35)</td><td valign="top" align="center" rowspan="1" colspan="1">95 (32)</td><td valign="top" align="center" rowspan="1" colspan="1">105 (35)</td><td valign="top" align="center" rowspan="1" colspan="1">240 (66)</td><td valign="top" align="center" rowspan="1" colspan="1">104 (35)</td><td valign="top" align="center" rowspan="1" colspan="1">111 (37)</td><td valign="top" align="center" rowspan="1" colspan="1">44 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">65 (20)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;BRAF</td><td valign="top" align="center" rowspan="1" colspan="1">1084 (37)</td><td valign="top" align="center" rowspan="1" colspan="1">322 (69)</td><td valign="top" align="center" rowspan="1" colspan="1">82 (28)</td><td valign="top" align="center" rowspan="1" colspan="1">62 (21)</td><td valign="top" align="center" rowspan="1" colspan="1">114 (38)</td><td valign="top" align="center" rowspan="1" colspan="1">185 (51)</td><td valign="top" align="center" rowspan="1" colspan="1">83 (28)</td><td valign="top" align="center" rowspan="1" colspan="1">96 (32)</td><td valign="top" align="center" rowspan="1" colspan="1">34 (11)</td><td valign="top" align="center" rowspan="1" colspan="1">106 (33)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;TRK</td><td valign="top" align="center" rowspan="1" colspan="1">533 (18)</td><td valign="top" align="center" rowspan="1" colspan="1">246 (52)</td><td valign="top" align="center" rowspan="1" colspan="1">57 (20)</td><td valign="top" align="center" rowspan="1" colspan="1">31 (11)</td><td valign="top" align="center" rowspan="1" colspan="1">29 (10)</td><td valign="top" align="center" rowspan="1" colspan="1">44 (12)</td><td valign="top" align="center" rowspan="1" colspan="1">43 (14)</td><td valign="top" align="center" rowspan="1" colspan="1">39 (13)</td><td valign="top" align="center" rowspan="1" colspan="1">18 (6)</td><td valign="top" align="center" rowspan="1" colspan="1">26 (8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;MET</td><td valign="top" align="center" rowspan="1" colspan="1">784 (27)</td><td valign="top" align="center" rowspan="1" colspan="1">284 (60)</td><td valign="top" align="center" rowspan="1" colspan="1">75 (26)</td><td valign="top" align="center" rowspan="1" colspan="1">40 (14)</td><td valign="top" align="center" rowspan="1" colspan="1">64 (21)</td><td valign="top" align="center" rowspan="1" colspan="1">136 (37)</td><td valign="top" align="center" rowspan="1" colspan="1">58 (19)</td><td valign="top" align="center" rowspan="1" colspan="1">45 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">27 (9)</td><td valign="top" align="center" rowspan="1" colspan="1">55 (17)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;HER2</td><td valign="top" align="center" rowspan="1" colspan="1">689 (23)</td><td valign="top" align="center" rowspan="1" colspan="1">266 (57)</td><td valign="top" align="center" rowspan="1" colspan="1">71 (25)</td><td valign="top" align="center" rowspan="1" colspan="1">31 (11)</td><td valign="top" align="center" rowspan="1" colspan="1">46 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">114 (31)</td><td valign="top" align="center" rowspan="1" colspan="1">45 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">48 (16)</td><td valign="top" align="center" rowspan="1" colspan="1">22 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">46 (14)</td></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">NGS used, n<xref rid="fnT2_2" ref-type="table-fn">
<sup>b</sup>
</xref> (%)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=820)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=291)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=71)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=49)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=75)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=137)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=74)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=58)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=19)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=46)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;&#8195;Yes</td><td valign="top" align="center" rowspan="1" colspan="1">628 (77)</td><td valign="top" align="center" rowspan="1" colspan="1">251 (86)</td><td valign="top" align="center" rowspan="1" colspan="1">58 (82)</td><td valign="top" align="center" rowspan="1" colspan="1">27 (55)</td><td valign="top" align="center" rowspan="1" colspan="1">51 (68)</td><td valign="top" align="center" rowspan="1" colspan="1">99 (72)</td><td valign="top" align="center" rowspan="1" colspan="1">41 (55)</td><td valign="top" align="center" rowspan="1" colspan="1">51 (88)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (68)</td><td valign="top" align="center" rowspan="1" colspan="1">37 (80)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;&#8195;No</td><td valign="top" align="center" rowspan="1" colspan="1">192 (23)</td><td valign="top" align="center" rowspan="1" colspan="1">40 (14)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (18)</td><td valign="top" align="center" rowspan="1" colspan="1">22 (45)</td><td valign="top" align="center" rowspan="1" colspan="1">24 (32)</td><td valign="top" align="center" rowspan="1" colspan="1">38 (28)</td><td valign="top" align="center" rowspan="1" colspan="1">33 (45)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (12)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (32)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (20)</td></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Results of <italic toggle="yes">RET</italic> gene fusion assessment at advanced diagnosis, n (%)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=820)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=291)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=71)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=49)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=75)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=137)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=74)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=58)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=19)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=46)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;&#8195;Positive</td><td valign="top" align="center" rowspan="1" colspan="1">39 (4.8)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (2.7)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (26.8)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (6.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (1.3)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (2.2)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (3.4)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (5.3)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (4.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;&#8195;Negative</td><td valign="top" align="center" rowspan="1" colspan="1">781 (95.2)</td><td valign="top" align="center" rowspan="1" colspan="1">283 (97.3)</td><td valign="top" align="center" rowspan="1" colspan="1">52 (73.2)</td><td valign="top" align="center" rowspan="1" colspan="1">46 (93.9)</td><td valign="top" align="center" rowspan="1" colspan="1">74 (98.7)</td><td valign="top" align="center" rowspan="1" colspan="1">134 (97.8)</td><td valign="top" align="center" rowspan="1" colspan="1">74 (100)</td><td valign="top" align="center" rowspan="1" colspan="1">56 (96.6)</td><td valign="top" align="center" rowspan="1" colspan="1">18 (94.7)</td><td valign="top" align="center" rowspan="1" colspan="1">44 (95.7)</td></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">RET</italic> test results available prior to initiation of therapy for advanced disease, n (%)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=820)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=291)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=71)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=49)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=75)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=137)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=74)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=58)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=19)</th><th valign="top" align="center" rowspan="1" colspan="1">(base n=46)</th></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;&#8195;Yes</td><td valign="top" align="center" rowspan="1" colspan="1">689 (84)</td><td valign="top" align="center" rowspan="1" colspan="1">249 (86)</td><td valign="top" align="center" rowspan="1" colspan="1">53 (75)</td><td valign="top" align="center" rowspan="1" colspan="1">39 (80)</td><td valign="top" align="center" rowspan="1" colspan="1">70 (93)</td><td valign="top" align="center" rowspan="1" colspan="1">113 (82)</td><td valign="top" align="center" rowspan="1" colspan="1">56 (76)</td><td valign="top" align="center" rowspan="1" colspan="1">55 (95)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (74)</td><td valign="top" align="center" rowspan="1" colspan="1">40 (87)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;&#8195;No</td><td valign="top" align="center" rowspan="1" colspan="1">119 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">37 (13)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (21)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (18)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">24 (18)</td><td valign="top" align="center" rowspan="1" colspan="1">18 (24)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (26)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (13)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#8195;&#8195;Unknown</td><td valign="top" align="center" rowspan="1" colspan="1">12 (1)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (2)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (4)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (5)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td></tr></tbody></table><table-wrap-foot><fn id="fnT2_1"><label>a</label><p>Number of patients with data for each parameter unless indicated otherwise.</p></fn><fn id="fnT2_2"><label>b</label><p>Base numbers reflect patients with aNSCLC who had RET-fusion test results (positive or negative) available at the time of data collection.</p></fn><fn><p>ALK, anaplastic lymphoma kinase; aNSCLC, advanced non-small cell lung cancer; BRAF, v-raf murine sarcoma viral oncogene homolog B1; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; KRAS, Kristen rat sarcoma; MET, mesenchymal epithelial transition factor receptor; NGS, next-generation sequencing; PD-L1, programmed cell death ligand 1; <italic toggle="yes">RET</italic>, rearranged during transfection; ROS1, c-ros oncogene 1; TRK, tropomysin receptor kinase.</p></fn></table-wrap-foot></table-wrap><p>The percentage of patients receiving chemotherapy (33% vs. 32%) or chemotherapy plus immunotherapy (19% vs. 18%) as first-line treatment was very similar between the overall aNSCLC cohort and the <italic toggle="yes">RET</italic> fusion-positive cohort (<xref rid="T3" ref-type="table">
<bold>Table&#160;3</bold>
</xref>). In the <italic toggle="yes">RET</italic> fusion-positive cohort, across the eight countries evaluated, chemotherapy was prescribed for 9&#8722;57%, and chemotherapy plus immunotherapy for 7&#8722;33%, in the first-line setting (<xref rid="T3" ref-type="table">
<bold>Table&#160;3</bold>
</xref>). Compared to the overall aNSCLC cohort, the percentage of patients treated with immunotherapy only (18% vs. 9%) or with targeted therapy (26% vs. 16%) was numerically lower in the <italic toggle="yes">RET</italic> fusion-positive cohort.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table&#160;3</label><caption><p>First-line drug treatment class among the overall aNSCLC cohort and <italic toggle="yes">RET</italic> fusion-positive cohort and by country for the <italic toggle="yes">RET</italic> fusion-positive cohort.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1">Parameter</th><th valign="top" align="center" rowspan="1" colspan="1">Overall aNSCLC cohort<break/>(n=2947)</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">RET</italic> fusion-positive cohort (n=576)</th><th valign="top" align="center" rowspan="1" colspan="1">USA (n=106)</th><th valign="top" align="center" rowspan="1" colspan="1">Brazil (n=70)</th><th valign="top" align="center" rowspan="1" colspan="1">UK (n=88)</th><th valign="top" align="center" rowspan="1" colspan="1">Italy (n=56)</th><th valign="top" align="center" rowspan="1" colspan="1">France (n=67)</th><th valign="top" align="center" rowspan="1" colspan="1">Spain (n=85)</th><th valign="top" align="center" rowspan="1" colspan="1">Germany (n=77)</th><th valign="top" align="center" rowspan="1" colspan="1">Taiwan (n=27)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Chemotherapy, n (%)</td><td valign="top" align="center" rowspan="1" colspan="1">977 (33)</td><td valign="top" align="center" rowspan="1" colspan="1">185 (32)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (9)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (20)</td><td valign="top" align="center" rowspan="1" colspan="1">29 (33)</td><td valign="top" align="center" rowspan="1" colspan="1">32 (57)</td><td valign="top" align="center" rowspan="1" colspan="1">25 (37)</td><td valign="top" align="center" rowspan="1" colspan="1">40 (47)</td><td valign="top" align="center" rowspan="1" colspan="1">23 (30)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (44)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chemotherapy plus immunotherapy, n (%)</td><td valign="top" align="center" rowspan="1" colspan="1">548 (19)</td><td valign="top" align="center" rowspan="1" colspan="1">104 (18)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (12)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (13)</td><td valign="top" align="center" rowspan="1" colspan="1">29 (33)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (11)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (19)</td><td valign="top" align="center" rowspan="1" colspan="1">17 (20)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (19)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Immunotherapy, n (%)</td><td valign="top" align="center" rowspan="1" colspan="1">523 (18)</td><td valign="top" align="center" rowspan="1" colspan="1">52 (9)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (6)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (11)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (14)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (5)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (6)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (17)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Targeted therapy (+/- other), n (%)</td><td valign="top" align="center" rowspan="1" colspan="1">774 (26)</td><td valign="top" align="center" rowspan="1" colspan="1">92 (16)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (10)</td><td valign="top" align="center" rowspan="1" colspan="1">21 (30)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (5)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (5)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (22)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">23 (30)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (33)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Best supportive care only, n (%)</td><td valign="top" align="center" rowspan="1" colspan="1">51 (2)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (2)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (1)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (10)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (2)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (1)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (1)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Other, n (%)</td><td valign="top" align="center" rowspan="1" colspan="1">70 (2)</td><td valign="top" align="center" rowspan="1" colspan="1">129 (22)</td><td valign="top" align="center" rowspan="1" colspan="1">65 (61)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (16)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (14)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (20)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (12)</td><td valign="top" align="center" rowspan="1" colspan="1">17 (20)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (3)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (11)</td></tr></tbody></table><table-wrap-foot><fn><p>aNSCLC, advanced non-small cell lung cancer; <italic toggle="yes">RET</italic>, rearranged during transfection.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="s4"><label>4</label><title>Discussion</title><p>This observational study provides real-world data from nine countries on the clinical characteristics, biomarker testing, and treatment patterns of patients with aNSCLC, focusing on data from patients with <italic toggle="yes">RET</italic> fusion-positive aNSCLC and no other co-alterations. Demographic and clinical characteristics, such as median age (65 years; IQR 57&#8722;70), advanced disease stage at diagnosis, predominantly adenocarcinoma histology, and a relatively high proportion of never smokers among the <italic toggle="yes">RET</italic> fusion-positive cohort were generally as expected for this patient population (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B6" ref-type="bibr">6</xref>). However, other studies have reported a preponderance of female patients (<xref rid="B12" ref-type="bibr">12</xref>), whereas in our <italic toggle="yes">RET</italic> fusion-positive cohort, 43% were female.</p><p>The <italic toggle="yes">RET</italic> testing rate of 31% across the nine countries in this study is much lower than those for <italic toggle="yes">EGFR</italic> and <italic toggle="yes">ALK</italic> (&#8776;80%), the more established biomarkers for NSCLC. This has various clinical implications. First, <italic toggle="yes">RET</italic> is an emerging biomarker (<xref rid="B13" ref-type="bibr">13</xref>); selective RET inhibitors have been available only for the last 4 years but at the time of writing are still not widely available or reimbursed across all lines of therapy among the countries in this study, including Brazil and Taiwan (no access across any line of therapy) and France and Italy (no access for first-line therapy). As access to selective RET inhibitors expands, we expect testing rates to increase. Second, education and awareness for <italic toggle="yes">RET</italic> as an actionable biomarker needs to be pursued, as evidence clearly suggests that patients derive benefit when tested for <italic toggle="yes">RET</italic> and treated, if appropriate, with a selective RET inhibitor in the first-line setting (<xref rid="B14" ref-type="bibr">14</xref>). Third, as more actionable biomarkers emerge for NSCLC, broad testing with NGS should become the norm and this will help increase testing rates across the spectrum for all biomarkers. The 4.8% positivity rate for <italic toggle="yes">RET</italic> fusions in the overall aNSCLC cohort who were tested was somewhat higher than the expected rate of &#8776;1&#8722;2% for <italic toggle="yes">RET</italic> fusion-positive aNSCLC (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>), although the positivity rate was reduced to 2.7% after excluding data from Brazil, which had a positivity rate much higher than any other country (26.8%). The exact reason for this difference is not known.</p><p>The proportion of patients treated with first-line chemotherapy or chemotherapy plus immunotherapy was almost the same in both cohorts. However, the use of targeted treatment was numerically lower in the <italic toggle="yes">RET</italic> fusion-positive cohort than in the overall aNSCLC cohort, possibly because selective RET inhibitors were just becoming available at the time of the study. The use of immunotherapy was also numerically lower in the <italic toggle="yes">RET</italic> fusion-positive cohort, which appears to be consistent with the lower rate of PD-L1 expression &#8805;50% in this cohort.</p><p>Limitations of this study include its observational design, making it subject to potential biases inherent in non-randomized research, such as selection bias and confounding factors that could influence treatment choices and outcomes. For example, selection of consecutive patients may have resulted in over-representation of patients who consult more frequently. In addition, there may have been potential biases in selecting the <italic toggle="yes">RET</italic> fusion-positive cohort. This cohort included both a subgroup of patients with <italic toggle="yes">RET</italic> fusion-positive disease and no other co-alterations from the overall aNSCLC cohort and an oversample of those with <italic toggle="yes">RET</italic> fusion-positive disease and no other co-alterations, which may not accurately reflect the broader population of <italic toggle="yes">RET</italic> fusion-positive aNSCLC patients with varying molecular profiles. The retrospective study design using electronic patient records may have provided incomplete or inconsistent data across different sites, potentially affecting the accuracy of clinical information. The study was conducted across nine countries, which may have led to variability in treatment patterns and access to biomarker testing due to differences in healthcare systems, guidelines, and resources. Although 31% of patients in the overall aNSCLC cohort were tested for <italic toggle="yes">RET</italic> fusions, this may not represent the full patient population, and the availability of <italic toggle="yes">RET</italic> testing could be limited in some regions or settings, leading to underreporting of <italic toggle="yes">RET</italic> fusion-positive cases. It is also noteworthy that the study mainly focused on descriptive analysis of clinical characteristics and treatment patterns, rather than directly evaluating the effectiveness of different treatments in the <italic toggle="yes">RET</italic> fusion-positive cohort. This study was conducted almost 4 years ago and, while we believe the findings are still relevant, a repeat study should be performed to assess the impact of the advancements in diagnostic and treatment paradigms (e.g., availability of selective RET inhibitors) over these years.</p><p>In conclusion, this study provides insights into the clinical characteristics, biomarker testing, and treatment patterns of patients with <italic toggle="yes">RET</italic> fusion-positive aNSCLC and highlights the need for increased <italic toggle="yes">RET</italic> testing rates, preferably with NGS, with the option to treat with selective RET inhibitors in the event of <italic toggle="yes">RET</italic> fusion-positive disease.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to acknowledge Greg Plosker and Caroline Spencer (Rx Communications, Mold, UK) and Alan &#211; C&#233;illeachair (Global Scientific Communications Associate, Cork, Ireland) for medical writing assistance with the preparation of this manuscript, funded by Eli Lilly and Company.</p></ack><sec sec-type="data-availability" id="s5"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="s6"><title>Ethics statement</title><p>Study materials and protocol were reviewed and exempted by the Western Institutional Review Board (study protocol number AG8757) and were in full accordance with relevant legislation at the time of data collection. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>UK: Conceptualization, Methodology, Writing &#8211; review &amp; editing. GS: Writing &#8211; review &amp; editing. HB: Data curation, Formal analysis, Validation, Writing &#8211; review &amp; editing. CF: Writing &#8211; review &amp; editing, Conceptualization, Data curation, Formal analysis, Writing &#8211; original draft. TP: Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>UK, GS, and TP are all employees of, and minor shareholders in, Eli Lilly and Company. HB and CF are employees of Adelphi Real World, who conducted the survey.</p><p>The authors declare that this study received funding from Eli Lilly and Company. The funder was involved in the study design, analysis, decision to publish, and preparation of the manuscript.</p></sec><sec sec-type="disclaimer" id="s10"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Cancer.org</collab></person-group>. <article-title>Key statistics for lung cancer</article-title>. Available online at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html">https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html</uri> (Accessed <date-in-citation content-type="access-date">November 3, 2023</date-in-citation>).</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Planchard</surname><given-names>D</given-names></name><name name-style="western"><surname>Popat</surname><given-names>S</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>K</given-names></name><name name-style="western"><surname>Novello</surname><given-names>S</given-names></name><name name-style="western"><surname>Smit</surname><given-names>EF</given-names></name><name name-style="western"><surname>Faivre-Finn</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title>. <source>Ann Oncol</source>. (<year>2018</year>) <volume>29</volume>:<page-range>iv192&#8211;237</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/annonc/mdy275</pub-id><pub-id pub-id-type="pmid">30285222</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choudhury</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Drilon</surname><given-names>A</given-names></name></person-group>. <article-title>Decade in review: a new era for RET-rearranged lung cancers</article-title>. <source>Transl Lung Cancer Res</source>. (<year>2020</year>) <volume>9</volume>:<page-range>2571&#8211;80</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.21037/tlcr-20-346</pub-id><pub-id pub-id-type="pmcid">PMC7815364</pub-id><pub-id pub-id-type="pmid">33489819</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kohno</surname><given-names>T</given-names></name><name name-style="western"><surname>Nakaoku</surname><given-names>T</given-names></name><name name-style="western"><surname>Tsuta</surname><given-names>K</given-names></name><name name-style="western"><surname>Tsuchihara</surname><given-names>K</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Yoh</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer</article-title>. <source>Transl Lung Cancer Res</source>. (<year>2015</year>) <volume>4</volume>:<page-range>156&#8211;64</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.3978/j.issn.2218-6751.2014.11.11</pub-id><pub-id pub-id-type="pmcid">PMC4384213</pub-id><pub-id pub-id-type="pmid">25870798</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hess</surname><given-names>LM</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>YE</given-names></name><name name-style="western"><surname>Bhandar</surname><given-names>NR</given-names></name><name name-style="western"><surname>Sireci</surname><given-names>A</given-names></name></person-group>. <article-title>Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States</article-title>. <source>BMC Cancer</source>. (<year>2021</year>) <volume>21</volume>:<fpage>28</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12885-020-07714-3</pub-id><pub-id pub-id-type="pmid">33402119</pub-id><pub-id pub-id-type="pmcid">PMC7786962</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drilon</surname><given-names>A</given-names></name><name name-style="western"><surname>Oxnard</surname><given-names>GR</given-names></name><name name-style="western"><surname>Tan</surname><given-names>DSW</given-names></name><name name-style="western"><surname>Loong</surname><given-names>HHF</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M</given-names></name><name name-style="western"><surname>Gainor</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Efficacy of selpercatinib in <italic toggle="yes">RET</italic> fusion-positive non-small-cell lung cancer</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>383</volume>:<page-range>813&#8211;24</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2005653</pub-id><pub-id pub-id-type="pmcid">PMC7506467</pub-id><pub-id pub-id-type="pmid">32846060</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griesinger</surname><given-names>F</given-names></name><name name-style="western"><surname>Curigliano</surname><given-names>G</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>M</given-names></name><name name-style="western"><surname>Subbiah</surname><given-names>V</given-names></name><name name-style="western"><surname>Baik</surname><given-names>CS</given-names></name><name name-style="western"><surname>Dan</surname><given-names>TSW</given-names></name><etal/></person-group>. <article-title>Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial</article-title>. <source>Ann Oncol</source>. (<year>2022</year>) <volume>33</volume>:<page-range>1168&#8211;78</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.annonc.2022.08.002</pub-id><pub-id pub-id-type="pmid">35973665</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>P</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>V</given-names></name><name name-style="western"><surname>Courcy</surname><given-names>J</given-names></name><name name-style="western"><surname>Doslikova</surname><given-names>K</given-names></name><name name-style="western"><surname>Davis</surname><given-names>VA</given-names></name><name name-style="western"><surname>Karavali</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes</article-title>. <source>Curr Med Res Opin</source>. (<year>2023</year>) <volume>39</volume>:<page-range>1707&#8211;15</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1080/03007995.2023.2279679</pub-id><pub-id pub-id-type="pmid">37933204</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>European Pharmaceutical Market Research Association</collab></person-group>. <article-title>European pharmaceutical market research association (EphMRA) code of conduct</article-title> (<year>2019</year>). Available online at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ephmra.org/sites/default/files/2022-08/EPHMRA%202022%20Code%20of%20Conduct.pdf">https://www.ephmra.org/sites/default/files/2022-08/EPHMRA%202022%20Code%20of%20Conduct.pdf</uri> (Accessed <date-in-citation content-type="access-date">November 3, 2023</date-in-citation>).</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>US Department of Health and Human Services</collab></person-group>. <article-title>Summary of the HIPAA privacy rule</article-title> (<year>2003</year>). Available online at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hhs.gov/sites/default/files/privacysummary.pdf">https://www.hhs.gov/sites/default/files/privacysummary.pdf</uri> (Accessed <date-in-citation content-type="access-date">November 3, 2023</date-in-citation>).</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Health Information Technology</collab></person-group>. <article-title>Health information technology act</article-title> (<year>2009</year>). Available online at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.healthit.gov/sites/default/files/hitech_act_excerpt_from_arra_with_index.pdf">https://www.healthit.gov/sites/default/files/hitech_act_excerpt_from_arra_with_index.pdf</uri> (Accessed <date-in-citation content-type="access-date">November 3, 2023</date-in-citation>).</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ye</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Unique genetic characteristics and clinical prognosis of female patients with lung cancer harboring RET fusion gene</article-title>. <source>Sci Rep</source>. (<year>2020</year>) <volume>10</volume>:<fpage>10387</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-020-66883-0</pub-id><pub-id pub-id-type="pmid">32587276</pub-id><pub-id pub-id-type="pmcid">PMC7316706</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Jager</surname><given-names>VD</given-names></name><name name-style="western"><surname>Timens</surname><given-names>W</given-names></name><name name-style="western"><surname>Bayle</surname><given-names>A</given-names></name><name name-style="western"><surname>Botling</surname><given-names>J</given-names></name><name name-style="western"><surname>Brcic</surname><given-names>L</given-names></name><name name-style="western"><surname>B&#252;ttner</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries</article-title>. <source>Lancet Reg Health Eur</source>. (<year>2024</year>) <volume>38</volume>:<elocation-id>100838</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.lanepe.2024.100838</pub-id><pub-id pub-id-type="pmid">38476742</pub-id><pub-id pub-id-type="pmcid">PMC10928289</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>B</given-names></name><name name-style="western"><surname>Loong</surname><given-names>HH</given-names></name><name name-style="western"><surname>Park</surname><given-names>K</given-names></name><name name-style="western"><surname>P&#233;rol</surname><given-names>M</given-names></name><name name-style="western"><surname>Arriola</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>First-line selpercatinib or chemotherapy and pembrolizumab in <italic toggle="yes">RET</italic> fusion-positive NSCLC</article-title>. <source>N Engl J Med</source>. (<year>2023</year>) <volume>389</volume>:<page-range>1839&#8211;50</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMoa2309457</pub-id><pub-id pub-id-type="pmcid">PMC10698285</pub-id><pub-id pub-id-type="pmid">37870973</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>